{"classes":[{"categories":[{"measurements":[{"comment":"Third quartile could not be calculated","groupId":"OG000","lowerLimit":"3.48","upperLimit":"NA","value":"8.15"},{"groupId":"OG001","lowerLimit":"1.45","upperLimit":"3.48","value":"2.00"},{"comment":"No event occurred for single participant hence Median and Inter-quartile range could not be calculated","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"PFS defined as interval of time(in months) between date of first dose \\& earlier of date of disease progression \\& date of death due to any cause.Progression is participants(pt's)with MDS \\& with \\<5% blasts:\\>=50% increase in blasts to\\>5% blasts/pt's with 5-10% blasts:\\>=50% increase to \\>10% blasts, for pt's with 10-20% blasts:\\>=50% increase to \\>20% blasts,for pt's with 20%-30% blasts:\\>=50% increase to \\>30% blasts, for CTCL progression is \\>=25% increase in skin disease from Baseline/new tumors (T3\\[1 or more tumors(\\>=1cm diameter\\]) in pt's with T1(Limited patches,papules\\&/or plaques covering \\<10% of the skin surface;may further stratify into T1a \\[patch only\\] versus T1b \\[plaque+-patch\\]),T2(Patches,papules/plaques covering \\>=10% of skin surface;may further stratify into T2a\\[patch only\\]versus T2b \\[plaque+-patch\\]) orT4(Confluence of erythema covering \\>=80% body surface area) only skin disease/loss of response in those with CR/PR, increase of skin score of \\> sum of nadir +50% Baseline score.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG000","title":"Part 2: GSK525762 60 mg QD CTCL"},{"description":"Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Part 2: GSK525762 75 mg QD MDS"},{"description":"Participants CTCL were administered once daily oral dose of 80 mg GSK525762","id":"OG002","title":"Part 2: GSK525762 80 mg QD CTCL"}],"paramType":"MEDIAN","populationDescription":"All Treated Population.","reportingStatus":"POSTED","timeFrame":"Up to 36.4 weeks","title":"Part 2: Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}